During the past decade, PCR Oncology conducted 130 clinical trials. In the 10-year time frame, 130 clinical trials started and 60 clinical trials were completed, i.e. on average, 46.2% percent of trials that started reached the finish line to date. In the past 5 years, 47 clinical trials started and 41 clinical trials were completed. i.e. 87.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "PCR Oncology" #1 sponsor was "National Cancer Institute (NCI)" with 85 trials, followed by "SWOG Cancer Research Network" with 28 trials sponsored, "Alliance for Clinical Trials in Oncology" with 25 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 12 trials sponsored and "Children's Oncology Group" with 12 trials sponsored. Other sponsors include 7 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "PCR Oncology" #1 collaborator was "National Cancer Institute (NCI)" with 73 trials as a collaborator, "NRG Oncology" with 9 trials as a collaborator, "Canadian Cancer Trials Group" with 8 trials as a collaborator, "Cancer and Leukemia Group B" with 4 trials as a collaborator and "NCIC Clinical Trials Group" with 4 trials as a collaborator. Other collaborators include 21 different institutions and companies that were collaborators in the rest 23 trials.

According to Clinical.Site data, the most researched conditions in "PCR Oncology" are "Recurrent Squamous Cell Lung Carcinoma" (8 trials), "Stage IV Lung Cancer AJCC v8" (8 trials), "Invasive Breast Carcinoma" (7 trials), "Stage IV Squamous Cell Lung Carcinoma AJCC v7" (7 trials) and "HER2/Neu Negative" (6 trials). Many other conditions were trialed in "PCR Oncology" in a lesser frequency.

Most popular intervention types in "PCR Oncology" are "Drug" (135 trials), "Other" (101 trials), "Biological" (73 trials), "Procedure" (46 trials) and "Radiation" (21 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (51 trials), "Quality-of-Life Assessment" (42 trials), "Computed Tomography" (29 trials), "Biospecimen Collection" (28 trials) and "Nivolumab" (24 trials). Other intervention names were less common.

The vast majority of trials in "PCR Oncology" are 145 trials for "All" genders, 17 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "PCR Oncology". undefined are not yet recruiting, 47 are recruiting, 76 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 27 completed trials in PCR Oncology, 5 suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in PCR Oncology, 4 "Phase 1" clinical trials were conducted, 78 "Phase 2" clinical trials and 86 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".